CRF Health's TrialMax ePRO Instrument Achieves Validation Standard
CRF Health has now deployed spirometer integration together with the ACQ and AQLQ in several global studies on TrialMax Touch™ and TrialMax Slate™ with four major Pharmaceutical companies. Including these programs, CRF Health’s clinical reach and breadth using Professor Juniper’s instruments spans nearly 40 countries, 3000 patients, and more than 40 languages. In addition to these, CRF Health has deployed a further 15 studies using Professor Juniper’s ACQ and AQLQ instruments (but without spirometer integration).
TrialMax® solutions are available for 5 platforms including Windows, Windows Mobile, Android, Palm OS and Web, thus allowing clients to select the right platform, technology and hardware to support their clinical trials. The combination of CRF Health’s clinical expertise and innovation of ePRO collection methods, combined with patient engagement and retention tools, offer new ways to improve study execution and subject compliance.
In a recent study discussion, Professor Elizabeth Juniper commented, “I feel it is important, when evaluating a new technology device to determine whether it will give valid data, to keep in mind that validity is more likely to be achieved if the screen shots are similar to the original format especially when translating languages with longer text.”
“Professor Elizabeth Juniper’s diligence and research integrity is a model for the industry. We are excited to have had the opportunity to collaborate and to jointly achieve this industry milestone. It is through our engagement with researchers and instrument authors such as Professor Elizabeth Juniper that we continually enhance our regulatory rigor, technology competence and patient research integrity through
Related Links:
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Operational Strategies That Strengthened the NIMBLE Trial Design
September 16th 2025